HCPCS code J9177: Enfortumab vedotin billing guide 2026

Key Takeaways

HCPCS code J9177 describes Injection, enfortumab vedotin-ejfv (PADCEV), 0.25 mg, effective July 1, 2020, used for metastatic urothelial carcinoma.

One billable unit equals 0.25 mg, so dose calculation directly determines unit count on the claim.

J9177 is subject to mandatory JW and JZ modifier requirements under CMS policy for Medicare claims.

Practice management software like Pabau streamlines oncology drug claim submission with built-in modifier tracking and documentation workflows.

HCPCS code J9177 is a Level II HCPCS code that describes Injection, enfortumab vedotin-ejfv, 0.25 mg. CMS established this code effective July 1, 2020, following FDA approval of enfortumab vedotin-ejfv (brand name PADCEV) in 2019. The short descriptor used on claims is “Inj enfort vedo-ejfv 0.25mg.”

Because PADCEV is a high-cost oncology drug, using accurate claims management software to track HCPCS Level II drug codes like J9177 helps reduce keystroke errors and duplicate claim submissions.

J9177 falls within the chemotherapy drugs series (J9000-J9999), the range CMS uses for injectable antineoplastic and related therapeutic agents billed under Medicare Part B. In addition, the SEER CanMED oncology database categorizes J9177 under Immunotherapy, with a major drug class of Drug Antibody Conjugate and a minor drug class of Nectin-4.

What is enfortumab vedotin-ejfv (PADCEV)?

Enfortumab vedotin-ejfv is an antibody-drug conjugate (ADC) that links a monoclonal antibody targeting Nectin-4, a protein overexpressed on urothelial cancer cells, to a cytotoxic payload (monomethyl auristatin E, or MMAE). As a result, the antibody delivers the cytotoxin directly to tumor cells, limiting systemic exposure compared with conventional chemotherapy.

The FDA granted accelerated approval in December 2019 and later converted to regular approval, based on clinical trial data showing clear improvements in overall survival for patients with locally advanced or metastatic urothelial carcinoma (bladder cancer and related urothelial tumors).

PADCEV is administered intravenously on days 1, 8, and 15 of each 28-day cycle. It is supplied as a lyophilized powder in single-dose vials for reconstitution. Coders should note the single-dose vial status because it directly affects drug wastage billing under CMS policy.

Billing units and dose calculation for HCPCS code J9177

CMS assigned J9177 a billing unit of 0.25 mg per unit, matching its usual approach of using the smallest practical dose increment to allow for dose variability. This means the number of units billed equals the total milligrams administered divided by 0.25.

For example, a patient receiving 125 mg in one infusion requires 500 units billed (125 / 0.25 = 500).

Dose-based unit calculation examples

The prescribing information for PADCEV caps the dose at 125 mg regardless of body weight above 100 kg. Therefore, verify the administered dose against the pharmacy dispensing record before submitting the claim. Units billed should reflect the milligrams actually administered, not the vial size dispensed.

Medicare reimbursement rates and fee schedule for J9177

Medicare Part B reimburses most physician-administered drugs at Average Sales Price plus 6% (ASP+6%). For J9177, the West Virginia Bureau for Medical Services fee schedule (effective October 1, 2025) lists a payment limit of $36.743 per 0.25 mg unit.

CMS updates ASP pricing every quarter, so practices should always verify the current rate directly from the CMS Physician Fee Schedule lookup before processing claims.

Reimbursement methods

ASP+6% (typical Medicare): The standard Medicare Part B rate for drugs billed by physician offices and outpatient clinics under the buy-and-bill model.

WAC-based rates: When ASP data is unavailable for a new drug, CMS reimburses at Wholesale Acquisition Cost plus 3% (WAC+3%). However, J9177 now has established ASP data.

Hospital Outpatient Prospective Payment System (OPPS): Hospital outpatient departments bill J9177 under OPPS, where the drug is typically packaged into an Ambulatory Payment Classification (APC) group rather than paid at the ASP+6% rate used in physician offices. As a result, the reimbursement structure differs a lot between settings. This is separate from the administration codes themselves, such as CPT code 96401 for subcutaneous or intramuscular chemotherapy administration, which bill alongside the drug rather than in place of it.

Prior authorization: Commercial payers and some Medicare Advantage plans require prior authorization before PADCEV infusion. Since payer requirements vary, confirm authorization status and document the approved authorization number on the claim before submission. Practices using dedicated HIPAA-compliant documentation workflows, alongside a signed HIPAA authorization form, can attach authorization records directly to the patient encounter, reducing the risk of submission without coverage confirmation.

HCPCS code J9177 JW and JZ modifier requirements

J9177 appears clearly on the CMS JW Modifier and JZ Modifier Policy HCPCS Codes list, making modifier compliance mandatory for Medicare claims. Getting this wrong triggers audits and overpayment demands, since PADCEV’s high cost attracts scrutiny from Medicare Administrative Contractors (MACs). The same modifier discipline applies to other administration codes, including IV push billing under CPT code 96374.

JW modifier: Drug wastage billing

The JW modifier identifies the portion of a single-dose vial that was drawn but discarded. PADCEV is dispensed as a single-dose vial in 20 mg (NDC 51144-0020-xx) and 30 mg (NDC 51144-0030-xx) presentations. Because doses are weight-based and vials come in fixed sizes, wastage is common.

For example, a patient weighing 70 kg receives 87.5 mg (350 units of J9177). To prepare that dose, the provider uses three 30 mg vials (90 mg total), so the 2.5 mg of unused drug becomes wastage.

On the claim, bill 350 units of J9177 for the drug administered, plus a separate line with the JW modifier for the remaining 10 units (2.5 mg / 0.25 mg = 10 units) discarded. CMS reimburses JW-billed wastage at the same ASP+6% rate, provided the medical record documents the administered dose and wastage amount.

JZ modifier: Confirming zero wastage

When no drug is wasted, meaning the dose exactly matches vial content, the JZ modifier must be appended to J9177 to clearly declare zero wastage. This modifier signals CMS that the provider reviewed wastage and confirms none occurred.

Omitting JZ when wastage is zero raises audit flags, similarly to how a missing JW does when wastage is present. Documentation must confirm the administered dose equals the vial amount dispensed.

In addition to modifier accuracy, practices managing infusion drug billing can use the prescription management tools inside practice management software like Pabau to document administered drug quantities and vial usage at the point of care. This creates an audit trail that supports both the administered-dose line and the JW wastage line on the claim.

Reduce oncology billing errors with Pabau

Pabau's claims management tools help infusion practices track drug administration, modifiers, and ICD-10 documentation in one place, so claims submit clean the first time.

Book a demo

NDC codes associated with HCPCS code J9177

Many payers require National Drug Code (NDC) reporting alongside J9177 on outpatient drug claims. In addition, NDC reporting captures the specific product dispensed, including the lot number and NDC qualifier code.

The two established NDCs for PADCEV are listed below. Verify the specific NDC on the dispensed vial label before entering it on the claim, because product package changes can alter the last segment of the NDC.

On CMS-1500 claims, NDC is reported in box 24 using the qualifier N4 followed by the 11-digit NDC in 5-4-2 format, the unit qualifier UN (units), and the quantity dispensed. On UB-04 institutional claims, NDC is reported in the drug information loop (loop 2410 in the 837I transaction).

Confirm payer-specific NDC format requirements before submission, since reporting formats can differ between Medicare and commercial plans. Accurate diagnosis documentation matters just as much, because ICD-10 coding accuracy directly supports the broader claims process.

ICD-10 diagnosis codes paired with J9177

Every J9177 claim requires at least one ICD-10-CM diagnosis code establishing medical necessity. PADCEV is FDA-approved for locally advanced or metastatic urothelial carcinoma. The diagnosis codes listed below represent the most commonly paired codes. In addition, always document the specific site and laterality based on the patient’s pathology report and staging, which is often confirmed with imaging such as a PET scan (HCPCS code A9552).

Document the specific ICD-10-CM code in the medical record before coding the claim. Linking the diagnosis to the drug administration note, infusion flowsheet, and oncologist order closes the audit loop, and it helps to know who manages electronic health records at each stage of that process.

Consistent ICD-10 documentation supports accurate claim linkage across specialties, and the same coding discipline applies to other clinical areas that report similar diagnoses.

Related HCPCS codes for urothelial carcinoma treatment

Because urothelial carcinoma is treated across multiple drug classes, coders supporting oncology practices need to recognize codes that commonly appear alongside or instead of J9177, depending on the patient’s treatment regimen and line of therapy.

• J9177: Enfortumab vedotin-ejfv, 0.25 mg (PADCEV, ADC monotherapy or combination)
• J9299: Injection, pembrolizumab, 1 mg (KEYTRUDA, used in combination with enfortumab vedotin per EV-302 trial data)
• J9022: Injection, atezolizumab, 10 mg (TECENTRIQ, checkpoint inhibitor used in urothelial carcinoma)
• J9176: Injection, elotuzumab, 1 mg (adjacent J-code for reference, different indication)
• J9179: Injection, eribulin mesylate, 0.1 mg (adjacent J-code, different tumor type)
• 96413-96415: Chemotherapy administration codes (IV infusion) billed alongside the drug in specific settings.

The EV-302/KEYNOTE-A39 combination trial data supporting pembrolizumab plus enfortumab vedotin as first-line treatment for advanced urothelial carcinoma means that claims pairing J9177 and J9299 on the same date of service are clinically expected for many patients.

Therefore, the treatment plan documented in the medical record should reflect the approved combination protocol, since procedure code documentation and oncology care delivery are closely linked.

Place of service and claim submission for J9177

Where PADCEV is administered determines which claim form and reimbursement pathway apply. The table below summarizes the key differences between the three most common settings. Some practices also coordinate home infusion or specialty drug administration for patients who cannot travel to a physician office or hospital outpatient department.

Buy-and-bill is the most common purchasing model for physician-office PADCEV administration: the practice purchases the drug from a distributor, administers it, and bills the payer for the drug plus IV infusion administration. Keep acquisition cost records on file in case of audit.

In addition, specialty pharmacy distribution, where the pharmacy ships directly to the infusion site, affects how the drug cost is recorded on the claim, and should be confirmed with the payer before the first infusion. Practices running multi-location infusion operations can benefit from Pabau’s multi-location management tools to standardize documentation and billing workflows across sites.

Conclusion

Billing HCPCS code J9177 correctly requires precise unit calculations, mandatory JW or JZ modifier application, accurate NDC reporting, and paired ICD-10-CM diagnosis codes that establish medical necessity for urothelial carcinoma treatment.

However, each of these elements interacts with the others: a correct dose calculation means nothing if the JW wastage line is missing, and a clean modifier set does not protect a claim with a wrong or unsupported diagnosis code.

Pabau’s claims management software supports oncology and infusion practices with structured claim submission workflows, modifier tracking, and documentation linkage between the clinical encounter and the billing record. To see how Pabau handles oncology drug billing end to end, book a demo.

Continue your research

Need a compliance checklist for your infusion practice? Medical spa compliance checklist covers documentation, audit readiness, and regulatory alignment for outpatient clinical settings.

Tracking drug inventory across infusion visits? Inventory management software helps practices monitor drug stock, vial usage, and wastage records in real time.

Billing a different injectable this week? HCPCS code J0690 covers injection, cefazolin sodium, 500 mg.

Coding an ophthalmology visit too? ICD-10 code H47.49 covers disorders of the optic chiasm.

Supporting a patient’s mental health documentation? Our PTSD nursing care plan template gives you a starting point.

Frequently Asked Questions